Key Market Insight
The AI-Based Stroke Detection & Triage Platforms Market was valued at USD 2.11 Billion in 2026 and is projected to reach USD 15.19 Billion by 2036, expanding at a CAGR of 22% during the forecast period.
Market Size (2026)
USD 2.11 Billion
CAGR
22%
Forecast Value (2036)
USD 15.19 Billion
AI-Based Stroke Detection & Triage Platforms Market
22%CAGRUSD 2.11 Billion
Coverage, study period and deliverables
| Study Period | 2026-2036 |
|---|---|
| Historical Period | 2019-2025 |
| Market Size (2026) | USD 2.11 Billion |
| Forecast Value (2036) | USD 15.19 Billion |
| CAGR | 22% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Regions Covered | 5 |
| Segments | 5 |
| Companies Profiled | 6 |
2026 baseline and 2026-2036 forecast
AI-based stroke detection and triage platforms use artificial intelligence and machine learning to analyze stroke-related imaging and support rapid clinical communication. Common functions include detection of suspected large-vessel occlusion, assessment of brain imaging, automated scoring or prioritization, notification of neurovascular teams and coordination of time-sensitive treatment workflows. WHO reported 11.9 million new strokes and 93.8 million people living with stroke globally in 2021. FDA's 2018 authorization of Viz.AI Contact established a U.S. regulatory precedent for software that analyzes CT images and alerts specialists when a suspected large-vessel blockage is identified. The broader AI-powered acute stroke triage market was estimated at USD 2.11 billion in 2026 with a 22% CAGR to 2030; this report uses that estimate as a quantitative benchmark rather than representing it as a narrow platform-specific market size.
What this report covers
The AI-Based Stroke Detection & Triage Platforms Market report examines software platforms that use artificial intelligence to identify stroke-related imaging findings and accelerate emergency triage and specialist notification.
The report evaluates market drivers, restraints, opportunities, challenges, technology trends, industry developments, segmentation, regional dynamics, competitive positioning and regulatory requirements.
The analysis focuses on large-vessel occlusion detection, multimodal stroke imaging, workflow orchestration, emergency communication, telestroke integration and emerging prehospital applications.
Headline findings from the analysis
Drivers, restraints, opportunities and challenges shaping the market
How the market breaks down across the dimensions covered
Performance across the geographies this report covers
North America is the leading regional market for AI-powered acute stroke triage, supported by advanced stroke-care infrastructure, high adoption of medical imaging and AI, established telestroke networks and a mature regulatory environment. The United States has been an early commercialization market for AI stroke triage, including FDA authorization of Viz.AI Contact and subsequent clearances for additional stroke-triage systems.
North America is the largest regional market, supported by advanced stroke-care infrastructure, high adoption of medical imaging and AI, established telestroke networks and a mature regulatory environment. The United States has been an early commercialization market for AI stroke triage, including FDA authorization of Viz.AI Contact and subsequent clearances for additional stroke-triage systems.
Europe has strong clinical and research capabilities in stroke medicine, medical imaging and artificial intelligence, with adoption supported by specialized stroke centers and digital-health investment. Market expansion varies across countries because reimbursement, procurement, data governance and regulatory implementation differ between healthcare systems.
Asia Pacific is expected to be the fastest-growing region as stroke burden, healthcare digitization and advanced imaging infrastructure expand across major markets. Large patient populations and increasing investment in AI-enabled healthcare create substantial opportunities for automated stroke detection and triage platforms.
Latin America offers developing opportunities as stroke-care networks, diagnostic imaging capacity and telemedicine infrastructure expand. Adoption of AI triage can help extend specialist-supported workflows, although affordability, interoperability and access to advanced imaging remain important constraints.
The Middle East & Africa market is developing as healthcare systems invest in advanced imaging, digital health and specialized stroke services. AI triage can help connect hospitals with specialist networks and prioritize urgent cases, although infrastructure, workforce availability and reimbursement differences can limit adoption.
Market structure and the positioning of leading suppliers
Competition includes AI medical-imaging companies, stroke-specific software vendors and large medical-technology companies. Leading competitive factors include diagnostic performance, breadth of imaging algorithms, regulatory clearances, workflow integration, notification speed, interoperability and evidence of impact on clinical operations. Major companies identified in current market research include Viz.ai, RapidAI, Brainomix, Aidoc, Siemens Healthineers, GE HealthCare, Qure.ai, JLK and others.
Major Players
Companies analysed in the full deliverable
Viz.ai develops AI-powered clinical decision-support and care-coordination solutions, including Viz.AI Contact, which received FDA authorization for CT-based suspected stroke notification. RapidAI develops imaging and clinical workflow technologies for stroke care. Brainomix develops AI medical imaging software, including Brainomix 360 stroke triage functionality, with FDA-cleared products. Aidoc develops AI-based medical imaging analysis and workflow solutions. Qure.ai develops AI-based medical imaging solutions with applications across emergency and acute-care settings. Siemens Healthineers participates in the broader medical imaging and AI ecosystem supporting stroke diagnosis and workflow.
Viz.ai develops AI-powered clinical decision-support and care-coordination solutions, including Viz.AI Contact, which received FDA authorization for CT-based suspected stroke notification.
RapidAI develops AI-powered imaging and workflow technologies focused on stroke and vascular conditions, including tools supporting rapid assessment and clinical coordination.
Brainomix develops AI medical imaging software, including Brainomix 360 stroke triage functionality. Brainomix 360 Triage Stroke has received FDA 510(k) clearance.
Aidoc develops AI-powered medical imaging analysis and workflow solutions, including applications intended to support rapid identification and prioritization of acute findings.
Qure.ai develops AI-based medical imaging solutions used across emergency and acute-care applications, including stroke-related imaging workflows.
Siemens Healthineers provides medical imaging and AI technologies that support radiology and acute-care workflows, including stroke imaging environments.
Approval pathways and compliance considerations
In the United States, radiological computer-assisted triage and notification software is regulated as medical-device software. FDA's 2018 De Novo authorization of Viz.AI Contact established a classification that enabled subsequent devices with the same type of intended use to pursue the 510(k) pathway. Brainomix 360 Triage Stroke is an example of a later 510(k)-cleared system. Developers must demonstrate appropriate performance, safety and quality controls, while healthcare organizations must establish governance for clinical use of AI-generated alerts.
Where the market is expected to go next
The market is expected to move toward broader stroke-care platforms that integrate imaging interpretation, triage, notification, treatment selection and outcome support. Continued development of multimodal imaging algorithms, prehospital applications, telestroke connectivity and workflow analytics could expand the addressable market. Future adoption will depend on prospective clinical validation, interoperability, cybersecurity, regulatory oversight and demonstrated improvement in real-world stroke-care outcomes.
How these estimates were built and reconciled
This report combines government and regulatory records, peer-reviewed clinical evidence and commercial market research. The quantitative benchmark uses the broader AI-powered acute stroke triage market estimate of USD 2.11 billion in 2026 and a reported 22% CAGR through 2030. Annual 2026-2036 values in this JSON are model-derived by applying the 22% CAGR to the 2026 benchmark and should not be interpreted as individually published market estimates for the exact AI-based stroke detection and triage platforms niche. Clinical accuracy statistics are presented separately from market revenue estimates.
Interviews with manufacturers, providers and payers.
Regulatory filings, procurement records and vendor reporting.
Bottom-up sizing triangulated against reported revenue.
Common questions about this report
It is medical-device or clinical decision-support software that analyzes stroke-related imaging or data and helps identify suspected abnormalities, prioritize cases, notify specialists or coordinate time-sensitive stroke workflows.
Large-vessel occlusion detection is a major application, while other functions include intracranial hemorrhage detection, ASPECTS assessment, CT-perfusion analysis, workflow notification and treatment-selection support.
The main drivers include the urgent need to reduce stroke-treatment delays, increasing stroke burden, expansion of advanced imaging, telestroke networks, regulatory clearances and growing clinical evidence for AI-assisted triage.
North America is the largest region in the broader AI-powered acute stroke triage market.
Asia Pacific is identified as the fastest-growing region in current commercial market research for AI-powered acute stroke triage.
A 2026 systematic review and meta-analysis of 18 studies involving 12,946 patients reported pooled sensitivity of 0.89 and specificity of 0.92 for AI-assisted LVO detection on CTA. Performance can vary by occlusion location, imaging protocol and clinical setting.
Key challenges include generalization across hospitals and imaging systems, false-positive and false-negative alerts, workflow integration, clinical governance, cybersecurity, regulatory requirements and the need for prospective real-world evidence.
Chapters in the deliverable itself
Executive Summary
Market scope, quantitative benchmark and key findings.
Market Overview
Market definition, technology and clinical workflow.
Key Market Insights
Principal market observations and adoption factors.
Growth Drivers, Restraints and Opportunities
Factors influencing market development.
Industry Trends and Developments
Technology, clinical and regulatory developments.
Segmentation Analysis
Component, deployment, application, end-user and imaging-modality analysis.
Regional Analysis
Market dynamics across major geographic regions.
Competitive Landscape
Competitive structure and differentiation.
Company Profiles
Profiles of selected market participants.
Regulatory Landscape
Regulatory framework for AI stroke triage software.
Future Outlook
Technology and adoption outlook.
Methodology
Research sources, assumptions and quantitative methodology.
FAQs
Frequently asked questions about the market.
The complete deliverable carries the segmentation tables, regional models and forecast workbook behind the analysis on this page.
Licence pricing on request.
Need a different segmentation, region set or forecast horizon?
Request customisationInsights
BlogHealthcare IT
AI-enabled digital health software and Software as a Medical Device (SaMD) are moving from pilots to operational deployments—but success depends less on model novelty and more on evidence, workflow fit, and governance across the healthcare IT stack.
Read Article
BlogHealthcare IT
AI-enabled digital health and Software as a Medical Device (SaMD) are moving from pilot programs to operational deployments—driven by clinical capacity constraints, expanding data availability, and maturing regulatory expectations. This article maps the technology landscape, adoption drivers, constraints, and go-to-market implications for healthcare and medtech stakeholders.
Read Article
Briefings
NewsletterHealthcare IT
AI-enabled SaMD is increasingly bought and governed as a managed clinical capability—validation, workflow fit, monitoring, and accountability are becoming the differentiators.
Read Newsletter
Newsroom
Press ReleaseHealthcare IT
MedInsight (ResearchX) has published expanded research coverage examining AI-enabled digital health software and Software as a Medical Device (SaMD), with a focus on clinical adoption drivers, regulatory considerations, and commercialization dynamics across care settings.
Read Release
Get custom research on any market in the healthcare ecosystem, tailored to your business question. An analyst will scope the work, agree the method with you and deliver a model you can interrogate.